| 7.59 0.03 (0.4%) | 04-26 13:06 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.32  |
1-year : | 12.96 |
| Resists | First : | 9.69 |
Second : | 11.1 |
| Pivot price | 8.44 |
|||
| Supports | First : | 7.42 |
Second : | 6.17 |
| MAs | MA(5) : | 7.9 |
MA(20) : | 8.82 |
| MA(100) : | 9.91 |
MA(250) : | 8.95 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 7.9 |
| RSI | RSI(14): 32.8  |
|||
| 52-week | High : | 12.93 | Low : | 4.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDNA ] has closed above bottom band by 19.5%. Bollinger Bands are 5.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.81 - 7.86 | 7.86 - 7.89 |
| Low: | 7.42 - 7.48 | 7.48 - 7.52 |
| Close: | 7.48 - 7.57 | 7.57 - 7.63 |
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Mon, 22 Apr 2024
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in CareDx, Inc (NASDAQ:CDNA) - MarketBeat
Sun, 21 Apr 2024
CareDx, Inc (NASDAQ:CDNA) Position Trimmed by Sumitomo Mitsui Trust Holdings Inc. - MarketBeat
Thu, 18 Apr 2024
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last? - Yahoo Finance
Tue, 16 Apr 2024
CareDx Appoints John W. Hanna as New CEO and Board Member - TipRanks.com - TipRanks
Tue, 16 Apr 2024
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer - Business Wire
Mon, 01 Apr 2024
How CareDx (CDNA) Stock Stands Out in a Strong Industry - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 52 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 97.5 (%) |
| Shares Short | 5,180 (K) |
| Shares Short P.Month | 3,760 (K) |
| EPS | -3.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.07 |
| Profit Margin | -67.9 % |
| Operating Margin | -38 % |
| Return on Assets (ttm) | -12.9 % |
| Return on Equity (ttm) | -55 % |
| Qtrly Rev. Growth | -20.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.41 |
| EBITDA (p.s.) | -1.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -2.15 |
| PEG Ratio | -0.8 |
| Price to Book value | 1.5 |
| Price to Sales | 1.4 |
| Price to Cash Flow | -21.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|